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Background & Aims: Among patients with large colorectal sessile polyps or laterally 
spreading lesions, it is important to identify those at risk for submucosal invasive cancer 
(SMIC). Lesions with overt endoscopic evidence of SMIC are referred for surgery, although 
those without these features might still contain SMIC that is not visible on endoscopic 
inspection (covert SMIC). Lesions with a high covert SMIC risk might be better suited for 
endoscopic submucosal dissection (ESD) than for endoscopic mucosal resection (EMR). We 
analyzed a group of patients with large colon lesions to identify factors associated with 
SMIC, and examined lesions without overt endoscopic high risk signs to determine factors 
associated with covert SMIC. 
 
Methods: We performed a prospective cohort study of consecutive patients referred for 
EMR of large sessile or flat colorectal polyps or laterally spreading lesions (20 mm or greater 
in size) at academic hospitals in Australia from September 2008 through September 2016. 
We collected data on patient and lesion characteristics, outcomes of procedures, and 
histology findings. We excluded serrated lesions from the analysis of covert SMIC due to 
their distinct phenotype and biologic features. 
 
Results: We analyzed 2277 lesions (mean size 36.9 mm) from 2106 patients (mean age 
67.7 years; 53.2% male). SMIC was evident in 171 lesions (7.6%). Factors associated with 
SMIC included Kudo V pit pattern, a depressed component (0–IIc), rectosigmoid location, 0–
Is or 0–IIa+Is Paris classification, non-granular surface morphology, and increasing size. 
Following exclusion of lesions that were obviously SMIC or serrated, factors associated with 
covert SMIC were rectosigmoid location (odds ratio, 1.87; P=.01), combined Paris 
classification, surface morphology (odds ratios, 3.96–22.5), and increasing size (odds ratio, 
1.16/10 mm; P=.012). 
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Conclusions: In a prospective study of 2106 patients who underwent EMR for large sessile 
or flat colorectal polyps or laterally spreading lesions, we associated rectosigmoid location, 
combined Paris classification and surface morphology, and increasing size with increased 
risk for covert malignancy. Rectosigmoid 0–Is and 0–IIa+Is non-granular lesions have a high 
risk for malignancy, whereas proximally located 0–Is or 0–IIa granular lesions have a low 
risk. These findings can be used to inform decisions on which patients should undergo ESD, 
EMR, or surgery. ClinicalTrials.gov no: NCT02000141 
 
KEY WORDS: colon cancer, tumor, prognostic factor, prediction 
 
Introduction 
The prediction of submucosal invasive cancer (SMIC) is an integral part of the endoscopic 
evaluation of large colonic lesions.  Lesions with a high risk of SMIC require careful decision 
making in order to select the best therapeutic modality and optimize outcomes for the 
patient.   The gross morphology and surface characteristics of large colonic lesions have 
been shown to predict SMIC, but independently overestimate the risk in the majority of 
lesions and underestimate the highest risk lesions.  Existing classification systems have 
used data derived primarily from Japanese cohorts and are typically single centre and 
retrospective1,2. Most studies enrol primarily small or diminutive lesions which can easily be 
entirely viewed lesions en-face in one image3,4. Several studies utilise specialized 
magnification endoscopes or chromoendoscopy, tools which are not available to the majority 
of endoscopists worldwide1,5. The Paris classification6 is used to describe lesion morphology, 
however it was designed as a descriptive tool rather than a clinical risk stratification aide.  
Laterally spreading tumours (LSTs) have been characterised as granular, (LST-G) or non-
granular (LST-NG), however this classification in isolation poorly predicts SMIC1.  Overt 
SMIC is often readily manifest by a depressed or ulcerated component to the lesion or an 
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area of disrupted surface pit pattern.  The Kudo classification of surface pit patterns strongly 
predicts SMIC7,8, (Kudo V) but in lesions without these overt features, diminutive focal SMIC 
is often endoscopically undetectable.  An accurate method of stratifying the risk of 
endoscopically non-visible, or “covert” malignancy in these lesions is required in order to 
guide resection choice.   Any classification system should be simple to use and reflect 
clinical outcomes.  In a prior study we evaluated risk factors for SMIC by univariable analysis 
in a cohort of 479 patients referred for EMR9.  We identified Paris 0–IIa+c classification, 
LST-NG, and Kudo V as risk factors, and noted that the presence of multiple factors 
magnified risk.   
In the current study we identify the key clinical and endoscopic features associated with 
SMIC within this large prospective multicentre cohort.  We then excluded lesions with overt 
evidence of SMIC to identify factors associated with “covert” SMIC. Serrated lesions were 
excluded as they have biologic and phenotypic characteristics which fundamentally differ 
from conventional adenomas, and they also represent a minority of lesions.  We have used 
the identified factors to develop a pragmatic schema for guiding endoscopic resection 
decisions.  We also aim to examine whether these factors are associated with 
endoscopically curable superficial SMIC (SM1) or non-resectable deep SMIC (SM2/3).     
Materials and Methods  
Prospective observational multicentre data on consecutive patients referred to one of eight 
Australian academic hospitals for the management of large sessile and flat colorectal polyps 
or laterally spreading lesions (LSL) ≥20mm were analysed. The study period was from 
September 2008 to September 2016 and is registered as The Australian Colonic Endoscopic 
Resection (ACE) study (ClinicalTrials.gov NCT01368289 & NCT02000141). All lesions had 
been initially identified and referred by a nationally accredited consultant endoscopist. 
Institutional review board approval was obtained at each centre. Written informed consent 
was obtained from each patient on the day of the procedure. Data were recorded in a 
comprehensive centralized database.   
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All EMR procedures were performed by a study investigator or a senior therapeutic 
endoscopy fellow under direct supervision. All clinical investigators were gastroenterologists 
with significant prior colonic EMR experience after training in high-volume tertiary referral 
centers in Australia or overseas.  Colonoscopy was performed using Olympus 180 or 190 
series high-definition variable-stiffness colonoscopes (180/190 PCF/CF; Olympus, Tokyo, 
Japan). The EMR technique is standard across all centres, and has previously been 
described in detail9.  Data collection included patient and lesion characteristics, procedural 
events and outcomes, complications and scheduled follow up at 14 days, 4-6 and 16 
months. Data was prospectively collected at the time of patient admission, during, and then 
immediately after the procedure. Lesions were carefully examined in vivo by one of the study 
investigators at the initial endoscopy and classified according to Paris classification, Kudo Pit 
Pattern (KPP) and surface topography (LST-G, LST-NG or mixed).  Paris classification is a 
consensus international standard for defining superficial gastrointestinal lesion morphology6. 
Elevated (>2.5mm above the surrounding normal mucosa) sessile lesions are described as 
Type 0-Is and sessile lesions under 2.5mm classed as 0-IIa (slightly elevated), 0-IIb (flat) or 
0-IIc (slightly depressed).  Excavated lesions are classed as 0-III. KPP is a classification of 
the endoscopic appearance of surface mucosal crypts10. A type V pattern is a disorganised 
pit pattern associated with invasive malignancy.  Although initially described using 
magnification endoscopy, pit pattern can be discerned using high definition endoscopes 
although this has not been validated experimentally. Clinical follow-up for the index 
procedure was obtained at 14 days by structured telephone interview.  Histology data was 
also collected at this time.  All authors had access to the study data and reviewed and 
approved the final manuscript. 
Pathological Analysis 
Histologic specimens were analysed at their respective study centre pathology department.  
Results were then centrally collated on a prospectively maintained database. Surgical 
histology reports were obtained where patients had undergone surgical resection. In cases 
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where the underlying polyp type was not evident, primarily due to obliteration by invasive 
CRC, the case was reviewed and classified according to the morphology and molecular 
changes in the CRC.  
Data and Analyses 
SPSS statistical software (IBM Corp. 2012. IBM SPSS Statistics, Version 23.0. Armonk, NY) 
was used to analyze the data. All analyses were exploratory and two-tailed tests with a 
significance level of 5% were used throughout. No attempt was made to correct for multiple 
comparisons. Data analysis was per lesion, however for analyses that included patient level 
data where patients had two or more lesions resected in one procedure, the largest lesion 
was selected for analysis. Mann–Whitney U tests were used to test for differences in the 
distribution of age and lesion size. The Pearson χ2 or the Fisher exact test was used to test 
for association between categorical variables and outcome. Multiple logistic regression with 
backward stepwise variable selection was used to identify the independent predictors of 
outcomes of interest. Candidate variables with P values for association that were equal to or 
less than 0.1 on univariable analysis were considered as potential risk factors in multiple 
logistic regression analysis. Backward stepwise variable selection was used to identify the 
best-fitting model and independent factors associated with SMIC. Odds ratios with 95% 
confidence intervals (95%CIs) from the model were used to quantify the extent of this 
association.   
To determine factors associated with covert SMIC, lesions with endoscopically overt high 
risk features consistent with SMIC (Kudo V pit pattern, depressed Paris 0-IIc component) 
were excluded.  Lesions with serrated histology or a serrated endoscopic appearance were 
excluded as they typically have characteristic endoscopic findings, a generally lower risk of 
SMIC and fundamentally different biological behaviour11,12.  Non-dysplastic serrated lesions 
have identifiable features which allow them to be easily recognized13.  Sessile serrated 
polyps with dysplasia (SSP-D) may be more likely to endoscopically resemble conventional 
adenoma, so prospective lesion assessment may result in these being misclassified14–16.. 
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Moreover, SSP-D may be very rapidly progressive and represent only a small proportion of 
total lesions so it was thought that excluding these lesions would allow a more valid 
assessment of a group of conventional colon polyps with similar biological and phenotypic 
characteristics.  SSPs require a separate assessment schema and malignancy risk is 
predicted by endoscopically recognizable dysplasia14.  
Following these exclusions, univariable and multivariable analyses were then repeated as 
above to generate the best-fitting model and independent predictors of covert SMIC. 
Lesions with confirmed SMIC were examined to determine if the identified factors associated 
with covert SMIC were also associated with SM1 or SM2/3 invasion. 
All authors had access to the study data and reviewed and approved the final manuscript. 
 
Results  
2693 lesions were assessed in the study period. 121 lesions had missing histological data, 
89 lesions had incomplete Kudo classification data, 17 lesions had incomplete Paris 
classification data, 8 lesions had incomplete size data and 15 lesions had incomplete 
surface morphology data. 150 lesions had unclassifiable surface features, and 92 lesions 
had rare morphological type (Paris IIb, III).  Some lesions had more than one missing data 
type, so in total 416 lesions with missing, unclassifiable or rare data were excluded (15.4%).   
Overall 2277 lesions were assessed (mean size 36.9mm, splenic flexure and proximal 
64.4%) in 2106 patients (mean age 67.7 years, 53.2% male).  SMIC was evident in 171 
lesions (7.6%). Cohort characteristics are presented in Table 1. (Table 1) 
Factors associated with Submucosal Invasive Cancer 
Univariable analysis indicated that patient factors including age, sex and ASA score were 
not predictive of SMIC risk.  Key factors associated with SMIC were lesion characteristics 
including size, location, Paris classification, 0-IIc component and surface morphology. 
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Factors associated with SMIC on multivariable analysis are listed in Table 2.  (Table 2) The 
strongest independent predictor was identification of a Kudo V pit pattern (Odds Ratio (OR) 
12.1 (7.00-20.8) p<0.001).  Size was an independent predictor of SMIC, however the effect 
was modest and only just reached significance. All other variables had similar odds ratios 
ranging from 1.92-2.84.  
For lesions with Kudo type V pit pattern, the specificity for cancer prediction was 97.5% 
(95% CI, 96.7-98.1%), sensitivity 40.4% (95% CI, 33.3-47.8%), positive predictive value 
(PPV) 56.6% (95% CI, 47.7-65.0%) and negative predictive value (NPV) 95.3% (95% CI, 
94.3-96.1%).  Diagnostic accuracy was 93.2% (95% CI, 92.1-94.2%).  For lesions with a 
Paris 0-IIc component, the specificity was 95.9% (95% CI, 95.0-96.7%), sensitivity 21.1% 
(95% CI, 15.6-27.8%), PPV 29.3% (95% CI, 22.0-37.8%) and NPV 93.7% (95% CI, 92.6-
94.7%).  Diagnostic accuracy was 90.3% (95% CI, 89.0-91.4%). The high specificity and 
limited sensitivity of these findings means that there remained a large proportion of bland 
appearing lesions with undefined SMIC risk.    
Factors associated with “Covert” Submucosal Invasive Cancer 
In order to determine the risk of SMIC in lesions without overt endoscopic evidence of 
invasion, we excluded lesions with Kudo type V pit pattern and Paris 0-IIc (depressed) 
components. Serrated lesions were also excluded.   
Univariable analysis of this group identified the strongest remaining factors associated with 
covert SMIC; Paris classification, surface morphology, size and location. Multiple logistic 
regression indicated the best fitting factors were location, size and combined Paris 
classification and surface topography. (Table 3). 
Assessing SMIC risk using these factors provided a stratification effect. (Figure 1) Proximal 
0-IIa G or 0-Is G lesions had the lowest risk of SMIC (0.7% and 2.3%), whereas distal 0-Is 
NG lesions had the highest risk (21.4%).  Increasing size had a minor effect when risk was 
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stratified per 10mm increase in size, however it had a more marked effect when the size 
cutoff was set at 50mm. 
SMIC risk in the total cohort according to the risk factors identified in the multivariable model 
was then compared to the group with covert SMIC.  (Table 4).
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For granular lesions with SMIC, few display overt endoscopic evidence of submucosal 
invasion.   As a result, the rates of SMIC are minimally changed when comparing the occult 
group with the total cohort.  The rates of endoscopically overt SMIC are considerably higher 
for NG lesions, however despite this, for 0-Is NG or 0-IIa+Is NG lesions there remains a 
substantial (>10%) risk of SMIC even when lesions with overt evidence of SMIC are 
excluded.  One lesion type that differs from the pattern is 0-IIa NG lesions. Once lesions with 
overt evidence of SMIC are excluded, these lesions have a low risk (4.2%) of harbouring 
underlying cancer.    
All lesion types have a poor sensitivity for the diagnosis of SMIC, however the 0-Is NG and 
0-IIa+Is NG lesions have specificities of 95.5% (95%CI 94.4-96.4) and 94.5% (95%CI 93.3-
95.5) respectively. 
(Table 5). 
Superficial SMI – Potential for Curative Resection 
Of the 138 lesions with covert SMIC, 64 were SM1 and potentially amenable to cure by 
endoscopic resection (41.6%, 3.7% of the total cohort). No lesion type identified by the 
multivariable model for covert SMIC was associated with a higher proportion of SM1 
disease.  (Supplementary Table 1). The analysis was also performed for the entire cohort, 
and there were similarly no associations with lesion type.  (Supplementary Table 2).  
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Discussion:  
The decision to undertake endoscopic resection of any colonic lesion hinges on the 
underlying risk of SMIC.  For lesions with overt endoscopic signs of deep SMIC (Kudo V, 
Paris 0-IIc component), endoscopic resection is not recommended and surgical resection is 
favoured unless there are compelling comorbidities that preclude surgery.  Deep SMIC is 
associated with higher rates of lymph node metastasis so even if ER is successful, surgical 
resection and removal of locoregional LNs is required to stage disease and reduce the risk 
of further metastatic spread17.  Existing endoscopic predictors of SMIC are specific, but have 
poor sensitivity, meaning that a large proportion of lesions may harbour cancer without 
displaying overt evidence of this.   
In this study we have defined the key risk factors for SMIC in a large prospective, 
multicentre, intention to treat cohort of lesions referred for EMR.  The strongest predictor of 
SMIC was Kudo V pit pattern (OR 14.2; p <0.001), and if this is present endoscopic 
resection is not advised.   A depressed (0-IIc) component to the lesion is also an 
independent predictor of SMIC which may preclude resection. Separately to these overt 
endoscopic predictors of SMIC, four key variables (Distal location, increasing size, Paris 
type and surface morphology) are associated with elevated risk of occult cancer.  Combining 
Paris type and surface morphology allows accurate stratification of SMI risk in large colonic 
lesions.  Distally located 0-Is and 0-IIa+Is NG lesions have a high risk of SMIC whereas 
proximally located 0-Is G or 0-IIa G lesions a very low risk.   The system is simple and easily 
applicable in clinical practice.  It is pragmatic and readily adoptable, using existing 
assessment tools available to every endoscopist, and is derived from prospective, 
multicentre data.  It helps endoscopists to grapple with the fact that the majority of colonic 
lesions encountered will be low risk.  In fact, lesions with an SMIC risk of <5% make up 
~75% of the cohort.   Endoscopic resection strategy decisions can be more acutely focused 
on higher risk lesions. 
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Prediction of SMIC for LSL is currently flawed and a simple SMIC risk stratification system 
does not exist.  Contemporary paradigms rely on identifying specific overt high risk factors 
such as 0-IIc morphology or KPP V in isolation4,9. An extension of the original NICE 
classification to identify deep SMIC has been developed using a small series of selected still 
images which demonstrated high (>90%) sensitivity and specificity when validated by trained 
novice raters18.  Despite this, there are no published prospective clinical validation studies, 
and preliminary data from a Spanish prospective multicentre study of 824 lesions (546 
sessile) showed that while specificity was satisfactory at 94.7% (95% CI, 92.8-96.7), 
sensitivity was poor at 60.0% (95% CI, 55.8-64.2). These results are similar to the results 
obtained in this study for the entire cohort assessing KPP V (specificity 97.1% (95% CI, 
96.2-97.8%), sensitivity 41.4% (95% CI, 34.0-49.2%).  It emphasises that when SMIC is not 
endoscopically evident, it is not possible to completely exclude.  The perfect endoscopic test 
for SMIC is unlikely to be achieved as not all cancers present a visible face to the surface.  
Buried, or diminutive foci are essentially “covert” and endoscopists require an accurate and 
useful risk stratification system to advise patients and guide resection in this context.   
Paris classification is used to describe lesion morphology, however it is cumbersome and 
rarely used by general endoscopists outside of research settings.  Interobserver variation 
has been questioned, particularly for smaller polyps19 and it does not specifically predict 
SMIC risk.   Kudo et al. classified colon lesions ≥10mm as laterally spreading tumours 
(LSTs) and characterised them as granular, (LST-G) or non-granular (LST-NG)20.  LST-NG 
is associated with SMI , however this binary classification is overly simplistic and poorly 
predicts lesions at very high or very low risk of SMIC21.  The Sano classification system 
identifies lesions at high risk of SMIC using narrow band imaging (NBI) (Olympus, Tokyo, 
Japan) assessment of the surface vasculature, however it has not been widely applied 
outside of initial validation studies22,23. Other features which may suggest submucosal 
invasion including probing the lesion with biopsy forceps to check for fixation, or submucosal 
injection to assess non-lifting.  These factors have deliberately not been assessed in this 
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study as they may not be appropriate to perform for endoscopists who will subsequently 
refer to a tertiary centre for resection.  Extensive biopsy or an unsuccessful attempt at 
resection of a lesion increases the difficulty for subsequent resection and is discouraged24. 
Non-lifting is strongly associated with deep submucosal invasive disease (SM3),25 however 
lesions with superficial invasion (SM1 and SM2) may still lift well as the underlying 
submucosa is not completely obliterated and may still expand26.  False positive non-lifting 
signs may also occur in the setting of submucosal fibrosis, biopsy or tattoo24,27.  In our study, 
non-lifting was associated with SMIC, however not all lesions were subjected to the lifting 
test if EMR was not attempted.   Non-lifting was observed in 20/2176 lesions, partial lifting in 
155/2176 and good lifting in 2001/2176 lesions.  SMIC was diagnosed in 4 non-lifting lesions 
(20%), 24 partially lifting lesions (15.5%) and 105 lesions with good lifting (5.2%), p=<0.001.   
Overall for any lesion with partial or non-lifting the unadjusted odds ratio for SMIC was 3.44 
(95%CI 2.19-5.39), p=<0.001.  
Expert endoscopists may have relied on a “gestalt” approach using several endoscopic risk 
factors together, however a risk stratification tool combining the strongest of these 
associated factors makes assessment more accessible and reproducible.  
The risk of SMIC in 0-IIa NG lesions is low when there are no overt endoscopic predictors 
evident.  The reason for this is likely that minimally elevated NG lesions are easy to 
comprehensively assess, as any SMIC is evident on the surface and not hidden by granular 
undulations or buried within a 0-Is nodule.  Comprehensive inspection of large G lesions is 
often challenging due to these factors resulting in hidden disease, but the underlying SMIC 
risk is lower overall reducing the clinical impact.   Size was relevant in the prediction of 
occult SMIC, however this was most prominent in lesions over 50mm in size, and in NG 
lesions with a 0-Is component (0-Is NG and 0-IIa+Is NG lesions).  It is likely that NG lesions 
of this size are considerably more biologically advanced than granular lesions of a similar 
size.  Size may be an additional factor compromising complete assessment of NG lesions 
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with a nodule, or extensive spreading granular lesions particularly if they also exhibit 
nodules.  (Figure 2.) 
Rates of SMIC in this study were markedly lower than in cohorts from “Eastern” 
investigators.  The overall rate of SMIC was 8.3% in this study, 3.5% in G lesions and 11.1% 
in NG lesions.  Yamada et al. report a rate of 29% in a cohort referred for endoscopic 
resection in Japan, 19% in G lesions and 39% in NG lesions.  Other studies have reported 
similar rates of SMIC in Japanese populations28–30.  This may represent biological 
differences or case selection, however it implies that the approach to endoscopic resection 
needs to be different in a Western setting.  The differences in risk between distal and 
proximal lesions were clearly noted in this study, however are not as prominent in cohorts 
from Japan.  There is clear evidence that there are biological differences depending on 
lesion location, however it may be that these are more pronounced in the West.  
The prediction of endoscopically resectable disease is not clarified by this study.  Stratifying 
SMIC risk according to the schema we have outlined does not delineate lesions with SM1 or 
SM2/3 disease.  It may be that a depressed component to a lesion represents an 
endoscopically visible early superficial focus for disease, whereas a nodule represents an 
obscured deeper focus.  Yamada et al. described risk factors for deep SMIC in 822 lesions 
≥10mm in a series of patients undergoing en-bloc ESD. Lesions undergoing EMR or 
piecemeal ESD were excluded biasing the series toward higher risk lesions, and reducing 
the applicability for endoscopists faced with a lesion where the decision on resection 
modality is yet to be made.  They demonstrated that a depressed component or a nodule 
both appear to be strongly associated with deep SM2/3 SMIC, however this was compared 
to all lesions rather than to SM1 disease31.  Our analysis likewise showed that Kudo V and a 
depressed component were good predictors of any SMIC.  Without tools to distinguish 
superficial versus deep invasion, it is impossible to clarify which lesions may fall into the 
narrow window where ESD is justified based on cost, safety and curative effectiveness.   
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This inability to accurately identify SM1 disease means that risk stratification for lesions 
without overt evidence of SMIC is vitally important for guiding resection decisions.   The 
benefit of ESD lies in its potential for curative resection for SM1 early CRC.  If all lesions in 
our cohort were subjected to ESD and assuming all ESD outcomes were perfect, the 64 
patients that were diagnosed with SM1 disease (3.4%) would benefit from a curative 
resection and avoid surgery.  ESD is however associated with a higher risk of surgery for 
adverse events over EMR (0.2% EMR32, 1% ESD33) and curative resection rates are at best 
90%33. This small net surgery sparing benefit must also take into account the significant 
resource, time and cost disadvantages of ESD, which in many time and budget-constrained 
health care systems would result in significantly reduced access to timely care for a large 
proportion of patients with large colonic LSL.  An alternative strategy based on the risks of 
SMIC established in this study would favour a selective ESD approach.  Where ESD is well 
established, with experienced operators, high success rates and low procedural adverse 
event risks, high risk lesions including distal 0-IIa NG lesions without overt evidence of 
SMIC, and all distal 0-Is or 0-IIa+Is lesions may be targeted by a primary ESD approach.  
This results in only 14% of patients undergoing ESD and ~10% of these ESDs resulting in a 
curative outcome.  Where ESD is less well established, an approach targeting rectal NG 
lesions may be appropriate as the risks of ESD are lower and the surgical adverse event 
rates considerable for low rectal surgery34.  
The strengths of this study include the large number of advanced lesions enrolled, and the 
completeness of follow up data.  The results represent “real-world” prospective assessment 
in a number of centres across Australia using standard colonoscopes without 
chromoendoscopy.  Variation, or errors in assessment are possible in these settings, but the 
large dataset reduces the impact of error and makes the findings more applicable to general 
clinical practice in a Western environment.   Lesions with ‘unclassifiable’ surface features 
were initially reported in the cohort, but as endoscopists have become more experienced 
over the course of the study these have declined in number.  No ‘unclassifiable’ lesions have 
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been reported since 2014.   Lesions with morphology consistent with serrated histology have 
been reported since an update to the study protocol in 2013 so this classification is not 
representative of all lesions in the cohort.   
Lesion location and gross morphology are strong predictors of SMIC and allow the 
endoscopist greater confidence in decisions regarding resection or referral for surgery.  
Clinical predictors of SMIC in colonic lesions are well studied, but factors that improve 
clinical decision making are lacking, particularly in an era where the availability of colonic 
ESD is increasing.  Distal non-granular lesions have a high risk of occult SMIC whereas 
proximal, granular 0-IIa lesions, after a careful assessment for features associated with 
SMIC, have a very low risk.   0-IIa NG lesions in the distal colon have a comparatively low 
risk of SMIC once overt features of malignancy are excluded.  In lesions without overt 
evidence of SMIC, the risks can be stratified according to these factors and used to 
rationalise an approach to endoscopic resection based on local availability, expertise and 
adverse event rates.  An informed and stratified approach is essential to mirror the disease 
process, choose the correct resection modality and thus minimise morbidity whilst optimising 
clinical outcomes.  
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FIGURE LEGENDS: 
Figure 1. 
Figure 2.  
(A) A 40mm 0-IIa G lesion in the ascending colon.  If there are no overt features of 
SMIC, this lesion has a 0.7% risk of covert malignancy.  
(B) A 50mm 0-IIa+Is G lesion at the hepatic flexure.  If there are no overt features of 
SMIC, this lesion has a 4.2% risk of covert malignancy.  
(C) A 50mm 0-Is NG lesion in the rectum.  Despite having no overt features of SMIC, this 
lesion still has a 21.4% risk of covert malignancy.  
(D) A 20mm 0-IIa NG lesion in the sigmoid colon.  0-IIa NG lesions have an overall 
23.4% risk of SMIC, however if lesions with overt features of SMIC are excluded 
(KPP V, any 0-IIc component), the risk falls to 6.4%. 
(E) A 40mm 0-IIa+c NG lesion in the distal transverse colon.  This lesion has a central 
depressed component (0-IIc) (F) and on close inspection (including with narrow band 
imaging) there is a disrupted pit pattern (Kudo Pit Pattern Vn). (G) Lesions with overt 
endoscopic evidence of SMIC are not suitable for resection and should be referred 
for surgical management.  
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TABLES 
Table 1. Characteristics of study patients and lesions 
 
 Patient Characteristics 
Patient Factors (n=2106) 
 
Age, years.  mean, (SD) 
 
67.7 (11.6) 
Range (18-95 years) 
Sex 
       Male 
       Female  
 
 
1119 (53.2%) 
983 (46.8%) 
 
ASA (n, %) 
       ASA 1 
       ASA 2 
       ASA 3 
       ASA 4 
       No data 
 
 
827 (41.1%) 
895 (44.5%) 
283 (14.1%) 
7 (0.3%) 
94 (4.5%) 
 
Lesion factors (n=2277) 
 
 
Lesion Size, mm. mean, (SD) 
 
 
36.9 (16.9) 
Range (20-180mm) 
 
Lesion Location (n, %) 
Rectum <5cm 
Rectum >5cm 
Sigmoid 
Descending Colon 
Splenic Flexure 
Distal Transverse 
Mid Transverse 
Proximal Transverse 
Hepatic Flexure 
Ascending Colon 
Cecum 
Cecum ICV Involved 
Cecum Appendiceal Orifice Involved 
 
 
121 (5.3%) 
304 (13.4%) 
241 (10.6%) 
98 (4.3%) 
46 (2.0%) 
62 (2.7%) 
101 (4.4%) 
95 (4.2%) 
163 (7.2%) 
543 (23.9%) 
387 (17.0%) 
92 (4.0%) 
22 (1.0%) 
 
Lesion Location (n, %) 
Rectum to Splenic flexure (Distal Colon) 
Distal transverse colon to Cecum (Proximal Colon) 
 
 
810 (35.6%) 
1465 (64.4%) 
 
Paris Classification (n, %) 
0-IIa 
0-Is 
0-IIa + Is  
 
 
1218 (53.5%) 
446 (19.6%) 
613 (26.9%) 
 
       
       Any 0-IIc component (0-IIa+c, 0-IIc) 
 
 
123 (5.4%) 
  
Morphology (n, %) 
Granular (LST-G) 
Non-Granular (LST-NG)  
Mixed  
Consistent with Serrated Morphology 
 
 
1439 (63.2%) 
583 (25.6%) 
161 (7.1%) 
94 (4.1%) 
 
Kudo type (n, %) 
       Kudo I 
       Kudo II 
       Kudo III 
       Kudo IV 
       Kudo V 
 
 
19 (0.8%) 
232 (10.2%) 
725 (31.8%) 
1179 (51.8%) 
122 (5.4%) 
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Histology 
 
 
Majority Polyp Histology (n, %) 
      Tubular Adenoma 
      Tubulovillous adenoma 
      Villous Adenoma 
      Sessile Serrated Polyp (SSP) 
      Traditional Serrated Adenoma (TSA) 
      Tubulovillous Adenoma with Serrated Component 
Invasive cancer only, no identifiable underlying polyp 
 
 
 
575 (25.3%) 
1245 (54.7%) 
59 (2.6%) 
308 (13.5%) 
30 (1.3%) 
41 (1.8%) 
19 (0.8%) 
 
 
Submucosal Invasive Cancer (SMIC) 
 
171 (7.6%) 
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Table 2. Risk of SMIC in all lesions according to study factors and best fitting multiple logistic 
regression model for factors associated with SMIC 
 
 No SMIC SMIC  p 
Patient Factors (n=2106) 
   
Age, years.  mean, (SD) 
 
67.6 (11.6) 
Range (18-95 
years) 
68.4 (11.6) 
Range (27-91 
years) 
0.58 
Sex 
       Male 
       Female  
 
 
1026 (91.7%) 
908 (92.4%) 
 
 
93 (8.3%) 
75 (7.6%) 
 
 
0.57 
ASA (n, %) 
       ASA 1 
       ASA 2 
       ASA 3 
       ASA 4 
 
755 (91.3%) 
830 (92.7%) 
259 (91.5%) 
7 (100.0%) 
 
72 (8.7%) 
65 (7.3%) 
24 (8.5%) 
0 (0.0%) 
 
0.66 
Lesion factors (n=2277) 
   
 
Lesion Size, mm. mean, (SD) 
 
 
36.5 (16.5) 
Range (20-
160mm) 
 
 
41.3 (20.7) 
Range (20-180mm) 
 
 
0.001 
Lesion Size 
        20-29.9mm 
        30-39.9mm 
        40-49.9mm 
        50+ mm 
 
 
717 (94.3%) 
572 (93.2%) 
360 (93.3%) 
457 (88.4%) 
 
 
43 (5.7%) 
42 (6.8%) 
26 (6.7%) 
60 (11.6%) 
 
 
0.002 
Lesion Size 
        20-49.9mm 
        50+ mm 
 
 
1649 (93.7%) 
457 (88.4%) 
 
 
111 (6.3%) 
60 (11.6%) 
 
 
<0.001 
Lesion Location (n, %) 
Rectum to Splenic flexure (Distal Colon) 
Distal transverse colon to Cecum (Proximal Colon) 
 
 
713 (88.0%) 
1393 (95.0%) 
 
 
97 (12.0%) 
74 (5.0%) 
 
 
<0.001 
Lesion Location (n, %) 
Rectum  
Sigmoid Colon  
Descending colon to Splenic Flexure (Distal Colon) 
Distal transverse colon to Cecum (Proximal Colon) 
 
 
378 (88.9%) 
201 (83.4%) 
134 (93.1%) 
1393 (95.0%) 
 
 
47 (11.1%) 
40 (16.6%) 
10 (6.9%) 
74 (5.0%) 
 
 
<0.001 
Lesion Location (n, %) 
Rectum and Sigmoid Colon (Rectosigmoid) 
Descending colon to Cecum 
 
 
579 (86.9%) 
1527 (94.8%) 
 
 
87 (13.1%) 
84 (5.2%) 
 
<0.001 
Paris Classification (n, %) 
0-IIa 
0-Is 
0-IIa + Is  
 
 
1158 (95.1%) 
399 (89.5%) 
549(89.6%) 
 
 
60 (4.9%) 
47 (10.5%) 
64 (10.4%) 
 
 
<0.001 
       
       No 0-IIc component  
       Any 0-IIc component (0-IIa+c, 0-IIc) 
 
 
2019 (93.7%) 
87 (70.7%) 
  
 
135 (6.3%) 
36 (29.3%) 
 
 
<0.001 
Morphology (n, %) 
Granular (LST-G) 
Non-Granular (LST-NG)  
Mixed 
Consistent with Serrated Morphology 
 
1372 (95.3%) 
510 (87.5%) 
131 (81.4%) 
93 (98.9%) 
 
 
67 (4.7%) 
73 (12.5%) 
30 (18.6%) 
1 (1.1%) 
 
 
<0.001 
Morphology (n, %) 
Granular (LST-G) 
Any Non-Granular component (LST-NG)  
Consistent with Serrated Morphology 
 
1372 (95.3%) 
641 (86.2%) 
93 (98.9%) 
 
 
67 (4.7%) 
103 (13.8%) 
1 (1.1%) 
 
 
<0.001 
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Kudo type (n, %) 
       Kudo I 
       Kudo II 
       Kudo III 
       Kudo IV 
       Kudo V 
 
 
19 (100.0%) 
228 (98.3%) 
698 (96.3%) 
1108 (94.0%) 
53 (43.4%) 
 
 
0 (0.0%) 
4 (1.7%) 
27 (3.7%) 
71 (6.0%) 
69 (56.6%) 
 
<0.001 
Kudo type (n, %) 
Kudo I-IV 
Kudo V  
 
 
2053 (95.3%) 
53 (43.4%) 
 
 
102 (4.7%) 
69 (56.6%) 
 
<0.001 
Excluded Lesions 
  
 
Unclassifiable surface features* 132 (91.0%) 13 (9.0%)  
Rare morphological type (Paris IIb, III)* 86 (96.6%) 3 (3.4%)  
   
 
*Missing data on histology in each group: Unclassifiable surface features n=5; rare morphological type n=3,  
Best Fitting Multiple Logistic Regression Model for factors associated with SMIC 
Best fitting multiple logistic regression model Adjusted OR P value 
 
Kudo type (n, %) 
       Kudo I-IV 
       Kudo V  
 
 
 
1 
14.2 (8.57-23.4) 
 
 
 
<0.001 
 
Size 
      Per 10mm increase 
 
 
 
1.12 (1.01-1.23) 
 
 
0.030 
 
Location Group  
      Rectum and Sigmoid Colon (Rectosigmoid) 
      Proximal Colon (Descending colon to Caecum) 
  
 
 
1.91 (1.31-2.79) 
1 
 
 
 
0.001 
 
Morphology (n, %) 
       Granular (LST-G) 
       Any Non-Granular (LST-NG) component 
       Other (not reported as LST-G, NG or mixed) 
 
 
 
1 
2.80 (1.89-4.16) 
0.72 (0.09-5.20) 
 
 
 
<0.001 
0.72 
 
Paris Classification  
       0-IIa 
       0-Is 
       0-IIa + Is  
 
 
 
1 
2.73 (1.64-4.55) 
2.49 (1.52-4.08) 
 
 
 
<0.001 
<0.001 
 
Any 0-IIc component 
       No 0-IIc component 
       Any 0-IIc component 
 
 
 
1 
1.80 (0.95-3.42) 
 
 
 
0.07 
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Table 3. Best fitting Multiple Logistic Regression model examining factors associated with 
Covert SMIC (Serrated histology, serrated surface features, Kudo type V and Paris 0-IIc lesions 
excluded) 
 
Best fitting multiple logistic regression model for factors associated with Occult SMIC 
Best fitting multiple logistic regression model Adjusted OR P value 
 
Location Group  
      Rectum and Sigmoid Colon (Rectosigmoid) 
      Proximal Colon (Descending colon to Caecum) 
  
 
 
1.87 (1.16-3.02) 
1 
 
 
 
0.010 
 
Combined Paris and Surface Features  
       0-IIa G 
       0-Is G 
       0-IIa + Is G  
        
       0-IIa NG 
       0-Is NG 
       0-IIa + Is NG  
 
 
 
1 
3.96 (1.24-12.7) 
6.11 (2.07-18.0) 
 
5.97 (1.92-18.5) 
22.5 (7.07-71.6) 
14.4 (4.53-45.5) 
 
 
 
0.020 
0.001 
 
0.002 
<0.001 
<0.001 
Lesion Size 
        Per 10mm increase 
 
 
1.16 (1.04-1.31) 
 
0.012 
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Table 4. Rates of SMIC in the total cohort and in lesions with potential covert SMIC according to 
location, morphology and surface characteristics. 
 
Lesions with potential “Covert” 
SMIC (n=1712) 
(Serrated histology, serrated surface features, 
Kudo type V and Paris 0-IIc lesions excluded) 
Total Cohort (n=2277) 
 
Proportion 
of cohort 
Proximal 
Colon 
RectoSigmoid 
Colon 
Proportion 
of cohort 
Proximal 
Colon 
Rectosigmoid 
Colon 
0-IIa G 
 
506 
29.5% 
3/422 
0.7% 
1/84 
1.2% 
634 
27.8% 
10/528 
1.9% 
1/106 
0.9% 
0-Is G 
  
299 
17.5% 
4/176 
2.3% 
7/123 
5.7% 
328 
14.4% 
6/193 
3.1% 
13/135 
9.6% 
0-IIa + 
Is G  
        
 
411 
24.0% 
9/212 
4.2% 
20/199 
10.1% 
477 
20.9% 
11/243 
4.5% 
26/234 
11.1% 
0-IIa 
NG 
 
312 
18.2% 
10/265 
3.8% 
3/47 
6.4% 
496 
21.8% 
29/413 
7.0% 
19/83 
22.9% 
0-Is 
NG 
 
85 
5.0% 
7/57 
12.3% 
6/28 
21.4% 
118 
5.2% 
14/73 
19.2% 
14/45 
31.1% 
0-IIa + 
Is NG  
 
99 
5.8% 
7/55 
12.7% 
7/44 
15.9% 
130 
5.7% 
13/71 
18.3% 
14/59 
23.7% 
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# NB:  Lesions not included in table from total cohort; 0-IIa Serrated surface n=88 (SMIC 1/85 
Proximal, 0/3 Rectosigmoid), 0-IIa+Is Serrated n=6 (SMIC 0/5 Proximal, 0/1 Rectosigmoid) 
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Table 5. Diagnostic Performance of Lesion Classification Types for Covert SMIC. 
 
Sensitivity Specificity Positive 
Predictive 
Value PPV 
Negative 
Predictive 
Value NPV 
Accuracy 
0-IIa G 
 
5.73%  
(3.05-10.5) 
70.0%  
(67.8-72.1) 
1.70% (0.90-3.20) 89.1% (87.4-90.7%) 64.6%  
(62.5-66.8%) 
0-Is G 
  
11.5%  
(7.38-17.4) 
83.2%  
(81.4-84.9%) 
5.83% (3.72-9.02) 91.2 (89.7-92.5) 77.3%  
(75.3-79.1) 
0-IIa + 
Is G  
        
 
22.9%  
(17.1-30.1) 
77.4%  
(75.3-79.3) 
8.39% (6.12-11.4) 91.7 (90.2-93.0) 72.8%  
(70.8-74.8) 
0-IIa NG 
 
27.4%  
(21.0-34.8) 
79.5%  
(77.5-81.32) 
10.8% (8.1-
14.2%) 
92.4% (90.9-93.6) 75.2% 
(73.2-77.1) 
0-Is NG 
 
16.6%  
(11.6-23.2%) 
95.5%  
(94.4-96.4) 
25.0% (17.7-34.1) 92.7% (91.4-93.8) 89.0%  
(87.5-90.3) 
0-IIa + 
Is NG  
 
15.9%  
(11.0-22.5) 
94.5%  
(93.3-95.5) 
20.7% (14.4-28.7) 92.6% (91.2-93.7) 88.0%  
(86.4-89.3) 
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Supplementary Tables 
Supplementary Table 1.   Submucosal invasion according to lesion morphology and surface 
characteristics in the “covert” cohort (n=1892). 
 SM1 SM2-3 p Missing 
0-IIa G 
 
0-Is G 
  
0-IIa + Is G  
        
0-IIa NG 
 
0-Is NG 
 
0-IIa + Is NG 
4 (44.4%) 
4 (22.2%) 
15 (41.7%) 
22 (52.4%) 
9 (34.6%) 
10 (40.0%) 
3 (33.3%) 
12 (66.7%) 
15 (41.7%) 
15 (35.7%) 
15 (57.7%) 
14 (56.0%) 
 
 
 
p=0.36 
2 (22.2%) 
2 (11.1%) 
6 (16.7%) 
5 (11.9%) 
2 (7.7%) 
1 (4.0%) 
Totals 64 
41.0% 
74 
47.4% 
18 (11.5%) 
N=138 
 
Supplementary Table 2.   Submucosal invasion according to lesion morphology and surface 
characteristics in the entire cohort (n=2277). 
 SM1 SM2-3 p Missing 
0-IIa G 
 
0-Is G 
  
0-IIa + Is G  
        
0-IIa NG 
 
0-Is NG 
 
0-IIa + Is NG 
5 (45.5%) 
4 (21.1%) 
16 (43.2%) 
24 (50.0%) 
9 (32.1%) 
10 (37.0%) 
4 (36.4%) 
13 (68.4%) 
15 (40.5%) 
18 (37.5%) 
16 (57.1%) 
15 (55.6%) 
 
 
p=0.53 
2 (18.2%) 
2 (10.5%) 
6 (16.2%) 
6 (12.5%) 
3 (10.7%) 
2 (7.4%)  
Totals 68 (39.8%) 82 (48.0%) 21 (12.3%) 
N=170 
NB: 1 lesion not included in this table: 0-IIa SM2/3 cancer with serrated surface appearance 
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STUDY PROTOCOL 
 
Project Title:  The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic 
Resection Prospective Observational Study. (ACE) 
 
Investigators:   Prof. Michael Bourkea,f, Dr Nicholas Burgessa 
 
Co-Investigators: Dr Stephen Williamsa 
Dr Luke Houriganb  
   Assoc. Prof. Gregor Brownd 
   Dr Simon Zanatid,e 
Assoc. Prof. Alan Mosse 
   Assoc. Prof Rajvinder Singhg 
   Dr Spiro Raftopoulosh 
   Dr Donald Ormondeh 
 
Sites:  Departments of Gastroenterology and Hepatology, Endoscopy Units:  
aWestmead Hospital, Sydney, NSW.  
   
bPrincess Alexandra Hospital, Brisbane, QLD  
   
dThe Alfred Hospital, Melbourne, VIC 
eWestern Hospital, Melbourne, VIC 
f Westmead Private Hospital, Sydney, NSW 
gLyell McEwin Hospital, Adelaide, SA 
hSir Charles Gairdner Hospital, Perth, WA 
    
 
Protocol Version:  3.0 
 
 
 
Background: 
Colonoscopic polypectomy is well established as an effective way of reducing colorectal cancer mortality1.  The 
majority of polyps detected and removed at colonoscopy are adenomas <10mm in size without advanced 
histology.  These lesions have a low risk of progression to malignancy and are relatively easily removed by 
standard snare polypectomy with low complication rates2.  Polyps that are sessile or flat and greater than 20mm 
in size are found in approximately 1% of all colonoscopies3 and are more difficult to manage.  These lesions, 
known as advanced mucosal neoplasia (AMN), have a high rate of advanced histology4.  Traditionally they have 
been managed by referral for open or laparoscopic surgery, which is definitive, but invasive, costly and 
associated with a significant mortality risk in patients with advanced age or comorbidities5.  Wide Field 
Endoscopic Mucosal Resection (WF-EMR) has emerged in recent years as an alternative to surgery that is now 
becoming the standard of care.  It is an outpatient procedure which is effective, safe and less costly than surgery 
when delivered at a tertiary referral centre6.  
The Australian Colonic Endoscopic Mucosal Resection study (ACE), is a multicentre prospective observational 
study which examined WF-EMR of colonic AMN (Ethics approval No. HREC JH/TG 2008/9/6.1(2858)).  This 
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project now has an extensive dataset from 8 leading colonic endoscopic resection centres in Australia on more 
than 1500 lesions resected over 4 years since June 2008.    
The ACE study has been successful in addressing several aspects of the resection of AMN, resulting in several 
high profile papers in internationally recognised journals.  The collection of this data has produced robust 
information on the efficacy of the procedure4, recurrence rates7, bleeding complications8 and mortality when 
compared to surgery5.  Single centre analysis of the ACE dataset at Westmead has also allowed insights into 
how to refine the procedure to improve outcomes. The target sign is now a recognised indication for the 
placement of clips to prevent perforation9, CO2 insufflation for WF-EMR has been shown to be superior to air 
insufflation10 and succinylated gelatin (Gelofusine®) has been shown to be superior to normal saline as a 
submucosal lifting agent11.  
There remain a number of unanswered questions regarding the endoscopic resection of large sessile lesions and 
expanding the ACE dataset in a new cohort of patients will allow these to be addressed.   Enhancing the 
prediction of submucosal invasive cancer, advanced lesion classification, refinement of the assessment of deep 
injury, submucosal injectate constituents, the optimum electrosurgical resection methods, prevention and 
prophylaxis of bleeding, and subtype analyses of the different histological groups comprising AMN will be 
examined.     
 
Literature Review: 
 
The ACE study was initially designed to assess the efficacy of and complications related to WF-EMR of AMN.  
AMN is uncommon, but is an important subgroup of bowel lesions as it contains a high proportion of incipient 
and inevitable bowel cancers. Few centres internationally have published studies on the resection of AMN and 
there are only 3 prospective studies which have accrued more than 200 patients12–14.  The focus of these studies 
was generally on technical efficacy, and data on complications or lesion subtypes was limited.  Through its 
unique dataset and collection of rare but clinically important lesions, the ACE study has provided an insight into 
the technical aspects of resection, and valuable data to examine other aspects of AMN itself.  
 
Since its inception in 2008, the ACE study has gathered data on over 1500 patients through a now well 
established tertiary referral service for the resection of AMN at 8 Australian major centres. The high throughput 
of cases and established research infrastructure means it has generated multiple internationally relevant studies 
and has adequate power to look at specific patient, lesion, technique and outcome subgroups.  Due to these 
positive results, the study has now created several questions that could be addressed by maintaining the same 
structure, but incorporating other study centres and broadening the data collection.   Technological advances in 
endoscopy have meant that real time prediction of lesion histology is becoming more accurate15, and the ACE 
study is well placed to expand lesion assessment data to provide robust evidence on the appearance of large 
colonic lesions and prediction of submucosal invasive cancer.  Important questions have arisen in recent years 
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as to what lesions are at high risk of progression to cancer16, which patients may harbour these high risk lesions 
and what is the best way to identify them.  The ACE study has the potential to focus on specific high risk lesion 
subtypes such as sessile serrated adenomas (SSAs) where there is little international data, and describe the 
histology of these lesions as well as link it to patient and procedural data.  The endoscopic appearance of SSAs 
is also poorly described17 and data will be collected on the prospective assessment of these lesions in the ACE 
study.   “Missed” lesions and interval cancer are also an important emerging aspect of colon lesions18,19, and 
detection of “missed” AMN may be valuable as an intermediate step before progression to cancer.  Along with 
these new insights into AMN, new aspects of resection will also be assessed in this prospective cohort.  A 
grading system for deep injury following WF-EMR will be added to the study and assessed to examine the 
effect of pro-active management of deep injury.  Kudo20 and Sano21,22 grades will be prospectively assessed for 
their prediction of sub mucosal invasive cancer.  Incremental improvement in refining the technique of WF-
EMR by scrutinizing ACE outcomes means that the acceptability and availability of the procedure is improved 
internationally, and it is seen as a safe, efficacious and cost effective technique.   
 
The ACE study has been valuable as a way of providing a base population for interventional studies.  Several 
studies will tie in to the expanded ACE data.  These studies will be independently submitted for HREC approval 
and review.  A prospective randomised controlled trial of the use of a prophylactic polysaccharide powder to 
prevent bleeding is planned as well as an assessment of soft coagulation at the margins of the EMR defect to 
prevent recurrence.   
 
 
Aims: 
 
To enhance understanding of the risk factors for AMN, improve lesion assessment and prediction of submucosal 
invasive cancer, improve endoscopic resection efficacy, reduce complications of WF-EMR and improve the 
understanding of the progression of large lesions to cancer.   
 
Methodology: 
 
Project Design: 
Prospective, observational multicentre study which aims to enrol all cases of AMN presenting to 8 
academic endoscopy units across Australia.   
 
Inclusion Criteria: 
• Patients referred for endoscopic resection of a large sessile colonic polyp or laterally spreading 
tumour ≥20mm in size. 
• Age > 18 years 
• Able to give informed consent to involvement in the clinical study 
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Exclusion Criteria: 
• Unable to provide informed consent for involvement 
 
Method of Screening: 
Patients referred to a study centre for colonic WF-EMR of a known sessile colonic polyp or laterally 
spreading tumour (LST) ≥20mm in size 
 
Sequence of Procedures: (for flowsheet see Appendix 1.) 
1. Patient is referred to one of 8 academic tertiary referral endoscopy units for removal of a large 
sessile colonic polyp or LST ≥20mm in size.  
2. All patients referred to this service are routinely mailed an information pack about the EMR 
procedure. If the referral information indicates that the patient is potentially eligible for the trial, 
written information about the study is included in this pack for the patient to read in advance of 
their arrival for the procedure. 
3. The patient reads the supplied information and consent form. 
4. Once checked into the endoscopy suite on the day of the procedure, the patient is met by one of 
the investigators to discuss the risks and benefits of the procedure and the study.  An interpreter 
is used to assist with the discussion if required.  
5. If the patient agrees to participate, the informed consent form is signed and witnessed with the 
help of an interpreter if required.  
6. If the patient decides not to participate, the colonoscopy and WF-EMR proceed as per usual.  
7. Patient enters the endoscopy room and the procedure commences.  
8. During the EMR procedure, data is recorded by the gastroenterology registrar or clinical 
research nurse regarding the technical aspects of the procedure.  
9. The patient is moved to recovery for observation.  They are observed for 2 hours in first stage 
recovery and at this stage are nil by mouth.  They are then observed in second stage recovery 
while consuming clear fluids for 4 hours.  They are examined by the proceduralist prior to 
discharge and provided with written post procedure information including a phone number to 
call in the event of any problems.  
10. Overnight they remain on a clear fluid diet and resume a normal diet the following day. 
11. Any adverse event is recorded prospectively on the data sheet as per the units standard practice.  
Adverse events include immediate or delayed bleeding, muscularis propria injury or 
perforation, persistent pain indicative of a serositis (inflammation of the outer layer of the 
bowel wall) or an unscheduled admission or readmission.  
12. Patients are contacted by the research nurse by telephone 14 days following their procedure to 
assess ongoing symptoms and advise of any adverse events including admissions.   
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13. The formal histology results of the resected specimens are recorded on the follow-up data sheet.  
The slides are also reviewed as per usual endoscopy unit practice in the monthly 
gastroenterology unit histopathology meeting.  
14. All patients return for a follow up procedure (scheduled colonoscopy) to check whether the 
lesion has been completely resected and to remove any recurrent or residual polyp.  For the 
majority of patients this is at 5 months at the centre that performed the initial resection.  A few 
patients will have lesions which are a low risk for recurrence and were resected “en-bloc”, these 
patients may be booked for a 12 month follow up procedure, which may be performed by the 
referring institution.  
15. Patients who have no, or low risk recurrence which is completely treated, are then followed up 
at 12 months, 3 years and 5 years at the referring institution. Endoscopy reports and histology 
are forwarded to the initial study centre for inclusion in the study.  Patients with high risk or 
incompletely treated recurrence are managed by further endoscopic resection, or referral for 
surgery.  This is based on the endoscopists assessment of the lesion and histology findings.  
16. Patients who have significant adverse events may have their records for this event reviewed to 
create a more detailed picture of the complication. 
17. The study outcomes will then be documented in manuscript form and submitted to a major 
internationally recognized peer reviewed journal for publication.  
18. All participants will be mailed a letter outlining the results of the trial, and thanking them for 
their involvement.  
19. All records of patients who participate in the trial will be marked so they are not destroyed by 
medical records for at least 15 years.  
 
Non-lifting lesions 
Lesions that are non-lifting will be removed using a stiff thin snare. The remaining tissue is removed by cold 
forceps avulsion and snare tip soft coagulation. 
 
Data Security: 
Patient data will be de-identified and a study code assigned to their information.  The study 
code will however be able to be used to re-identify the patient for the purposes of linking follow up information.  
All data entry will be performed by the Clinical Research Nurse on a password secured Filemaker Database. 
This database is held on a Westmead Hospital internal server with regular automated backups.  The database file 
is internally encrypted preventing patient data being visible by reading the source code. Paper datasheets 
collected are securely stored in a locked research office.  The Clinical Research Nurse is the custodian of both 
electronic and paper data storage.  
 
Participant Withdrawal From the Study: 
In accordance with the Declaration of Helsinki and the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Practice 
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Guidelines, a participant is free to withdraw from the study at any time for any reason without prejudice to their 
future medical care by the physician or the institution.  The Investigator may also withdraw the participant at 
any time in the interests of patient safety. Should a participant decide to withdraw, all efforts will be made to 
complete and report the observations as thoroughly as possible.  Participants may be removed from the study if 
one or more of the following events occur: 
• Withdrawal of consent 
• Decision made by the investigators that removal from the study is in the patients best 
medical interest. 
• Study stopped by ethics/regulatory authorities 
The primary reason and additional reasons for withdrawal will be recorded in the participants 
medical record. 
 
Statistics: 
The ACE study aims to enrol patients for 10 years.  At current rates of enrolment, this will result 
in 4000-5000 patients in the study.  Comparison of quantitative variables will be performed by Students t-test 
and for qualitative variables by Pearson’s χ2 -test. A p value of < 0.05 will be considered significant. Statistical 
analyses will be performed with SPSS statistical software (IBM Corp. 2012. IBM SPSS Statistics, Version 21.0. 
Armonk, NY) with the help of an independent statistician.   
 
Ethical Issues: 
All patients will be managed according to established best practice according to international 
research and consensus on WF-EMR.  Treatment does not differ according to whether or not the patient 
chooses to participate in the study. 
 The key ethical issues are: 
1. Dependent Relationships 
• Most eligible participants will not be the regular patients of the investigators or the 
colonoscopists involved in the study.  This is because the majority of the patients 
are referred from other medical specialists (Gastroenterologists or surgeons) to the 
tertiary referral service operated by the study centre Endoscopy Unit.  Follow up 
after confirmed curative WF-EMR is with the referring specialist. Vigilance in 
explaining the voluntary nature of participation will be exercised for all patients.  It 
will be emphasized that a decision not to enroll in the study will have no 
ramifications whatsoever for the patients care and ongoing relationship with the 
treating medical team. 
2. Conflict of Interest 
• None of the investigators have financial conflicts of interest. 
 
Potential Significance of the Study: 
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The ACE study has already produced internationally significant research output and the unique 
dataset is of considerable interest due to its potential to answer further questions about AMN and WF-
EMR.  The areas of research will cover epidemiological factors associated with large lesions, advanced 
lesion classification, refinement of the assessment of deep injury and subtype analyses of the different 
histological groups comprising AMN.  The research has the potential to influence advice on screening 
and surveillance of colorectal polyps and in particular large lesions, to improve the ability of 
endoscopists to identify and resect AMN safely and to improve the worldwide acceptance of endoscopic 
resection of AMN as an alternative to surgery, reducing costs for healthcare systems.   
 
Budget: 
The cost of investigator time is free.  
 
Funding for the project at is through the Westmead Hospital Endoscopy Research Fund. 
 
Budget: 
 Ethics Committee Application Fee  $50.00 
  
 ______________________________________ 
 Total:     $50.00 
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Appendix 1. 
Study Flowchart: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NB: *=cumulative time from study entry to typical follow up for patients without recurrence.   Follow up times are variable and are decided by the 
clinician at each procedure based on evidence of recurrence and histopathological findings. If recurrence occurs then typical subsequent follow 
up is 5 months, lesions without recurrence are followed up at 12 month, 3 year and then 5 year intervals. 
Patients may be referred for surgery at any time point based on endoscopic findings or histology.  
Patient referred for resection of flat or sessile colon polyp 20mm or greater in size 
Patients receive study information in mail along with 
procedure information pack 
 
Patient presents to study centre endoscopy unit 
for procedure 
Study investigator meets with patient, explains study, answers 
patient questions. 
Consent form signed by patient. 
Data collection Point 2 
Telephone follow up (14 days) 
 Performed by Study Research Nurse or Investigator 
Adverse Events 
 Histopathology data recorded 
  
Data collection Point 1 
Index Procedure              
Patient, procedure and polyp resection data 
Recovery 
 Observation 
 Monitoring for adverse events 
 Any admission details 
 
Data collection Point 3 
Scheduled Colonoscopy 1 (5 months)* 
 Procedure performed at study institution 
Recurrence and any treatment 
 Surgery details (if any) 
  
Data collection Point 4 
Scheduled Colonoscopy 2   (17 months)*  
 Procedure performed at study institution or referral centre. 
1 year following Scheduled Colonoscopy 1 
Recurrence and any treatment 
 Surgery details (if any) 
  
Data collection Point 5  
Scheduled Colonoscopy 3    (53 months)*  
 Procedure performed at study institution or referral centre. 
3 years following Scheduled Colonoscopy 2 
Recurrence and any treatment 
 Surgery details (if any) 
  
Data collection Point 6 
Scheduled Colonoscopy 4   (113 months)* 
 Procedure performed at study institution or referral centre. 
5 years following Scheduled Colonoscopy 3 
Recurrence and any treatment 
 Surgery details (if any) 
  
